Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor |

Key Technologies Highlighted as Late-Breakers at ACC.14

By Dave Fornell, DAIC editor

Data from several cutting-edge device clinical trials will be presented as late-breakers at the American College of Cardiology 63rd Annual Scientific Session & Expo (ACC.14), March 28-31.  

One of the most anticipated therapies on the interventional front is the use of renal denervation to treat drug resistant hypertension. However, its future was called into question recently when Medtronic announced it failed to meet the primary endpoints in its SYMPLICITY HTN-3 U.S. pivotal trial. The results of that trial will be presented at ACC on Saturday. Experts say this is not the end of the story, and additional data might be revealed in another late-breaker with data from the Global SYMPLICITY Registry. 

Also on the interventional front, the NEXT trial is among the first to compare a biodegradable polymer drug-eluting stent (DES) with a durable polymer DES. 

In electrophysiology, the use of cardiac resynchronization therapy (CRT) devices was expanded a few years ago to patients with mild heart failure. One of the late breakers will discuss long-term survival in this CRT population.

In structural heart, three key presentations are featured. The CHOICE Trial will compare self-expanding (Medtronic’s Corevalve) to balloon expandable (Edwards’ Sapien) TAVR devices. Another compares the Corevalve with surgical outcomes in patients deemed high risk for surgery. The final session will share one-year outcomes from the STS/ACC Transcatheter Valve Therapy Registry.

Complete list of ACC late-breaking trials

For information on ACC.14, the official site is accscientificsession.cardiosource.org 

Related Content

News | Renal Denervation

December 9, 2020 — SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to ...

Home December 09, 2020
Home
News | Renal Denervation

June 26, 2020 – New data from the Global SYMPLICITY Registry (GSR) showed that renal denervation (RDN) with the ...

Home June 26, 2020
Home
News | Renal Denervation

April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had ...

Home April 01, 2020
Home
News | Renal Denervation

April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had ...

Home April 01, 2020
Home
News | Renal Denervation

May 23, 2019 – Investigators unveiled late-breaking clinical data from a first-of-its-kind physician sponsored clinical ...

Home May 23, 2019
Home
Feature | Renal Denervation

May 30, 2018 — Despite the best efforts of clinicians to manage hypertension, it continues to increase and is now ...

Home May 30, 2018
Home
News | Renal Denervation

May 31, 2018 – ReCor Medical announced that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and ...

Home May 30, 2018
Home
News | Renal Denervation

May 23, 2018 – At the 2018 EuroPCR Annual Meeting in Paris, Medtronic announced first-ever-data from the SPYRAL HTN-ON ...

Home May 23, 2018
Home
News | Renal Denervation

April 16, 2018 — Medtronic plc announced U.S. Food and Drug Administration (FDA) approval to begin an investigational ...

Home April 16, 2018
Home
News | Renal Denervation

August 31, 2017 — Medtronic plc announced its intent to move forward with a new renal denervation pivotal trial ...

Home August 31, 2017
Home
Subscribe Now